These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8930168)

  • 21. Bent pseudoknots and novel RNA inhibitors of type 1 human immunodeficiency virus (HIV-1) reverse transcriptase.
    Burke DH; Scates L; Andrews K; Gold L
    J Mol Biol; 1996 Dec; 264(4):650-66. PubMed ID: 8980676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Calanolides, the naturally occurring anti-HIV agents.
    Xu ZQ; Flavin MT; Jenta TR
    Curr Opin Drug Discov Devel; 2000 Mar; 3(2):155-66. PubMed ID: 19649847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Augmentation of human immunodeficiency virus type 1 subtype E (CRF01_AE) multiple-drug resistance by insertion of a foreign 11-amino-acid fragment into the reverse transcriptase.
    Sato H; Tomita Y; Ebisawa K; Hachiya A; Shibamura K; Shiino T; Yang R; Tatsumi M; Gushi K; Umeyama H; Oka S; Takebe Y; Nagai Y
    J Virol; 2001 Jun; 75(12):5604-13. PubMed ID: 11356968
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polycitone A, a novel and potent general inhibitor of retroviral reverse transcriptases and cellular DNA polymerases.
    Loya S; Rudi A; Kashman Y; Hizi A
    Biochem J; 1999 Nov; 344 Pt 1(Pt 1):85-92. PubMed ID: 10548537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor.
    Sato A; Hammond J; Alexander TN; Graham JP; Binford S; Sugita K; Sugimoto H; Fujiwara T; Patick AK
    Antiviral Res; 2006 Jun; 70(2):66-74. PubMed ID: 16472877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and pharmacokinetics of single doses of (+)-calanolide a, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects.
    Creagh T; Ruckle JL; Tolbert DT; Giltner J; Eiznhamer DA; Dutta B; Flavin MT; Xu ZQ
    Antimicrob Agents Chemother; 2001 May; 45(5):1379-86. PubMed ID: 11302799
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Specific inhibition of human immunodeficiency virus type 1 reverse transcriptase mediated by soulattrolide, a coumarin isolated from the latex of calophyllum teysmannii.
    Pengsuparp T; Serit M; Hughes SH; Soejarto DD; Pezzuto JM
    J Nat Prod; 1996 Sep; 59(9):839-42. PubMed ID: 8864237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
    Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Susceptibility of feline immunodeficiency virus/human immunodeficiency virus type 1 reverse transcriptase chimeras to non-nucleoside RT inhibitors.
    Auwerx J; Esnouf R; De Clercq E; Balzarini J
    Mol Pharmacol; 2004 Jan; 65(1):244-51. PubMed ID: 14722257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and biological activity of novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 2-Aryl-substituted benzimidazoles.
    Roth T; Morningstar ML; Boyer PL; Hughes SH; Buckheit RW; Michejda CJ
    J Med Chem; 1997 Dec; 40(26):4199-207. PubMed ID: 9435891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase.
    Boyer PL; Sarafianos SG; Arnold E; Hughes SH
    J Virol; 2001 May; 75(10):4832-42. PubMed ID: 11312355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitors of human immunodeficiency virus type 1 reverse transcriptase target distinct phases of early reverse transcription.
    Hooker CW; Lott WB; Harrich D
    J Virol; 2001 Apr; 75(7):3095-104. PubMed ID: 11238836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-HIV natural product (+)-calanolide A is active against both drug-susceptible and drug-resistant strains of Mycobacterium tuberculosis.
    Xu ZQ; Barrow WW; Suling WJ; Westbrook L; Barrow E; Lin YM; Flavin MT
    Bioorg Med Chem; 2004 Mar; 12(5):1199-207. PubMed ID: 14980631
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum.
    Kashman Y; Gustafson KR; Fuller RW; Cardellina JH; McMahon JB; Currens MJ; Buckheit RW; Hughes SH; Cragg GM; Boyd MR
    J Med Chem; 1992 Jul; 35(15):2735-43. PubMed ID: 1379639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
    Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
    J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of a bound non-nucleoside RT inhibitor on the dynamics of wild-type and mutant HIV-1 reverse transcriptase.
    Zhou Z; Madrid M; Evanseck JD; Madura JD
    J Am Chem Soc; 2005 Dec; 127(49):17253-60. PubMed ID: 16332074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase.
    Boyer PL; Currens MJ; McMahon JB; Boyd MR; Hughes SH
    J Virol; 1993 Apr; 67(4):2412-20. PubMed ID: 7680393
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucleoside inhibitors zidovudine and 3-TC.
    Krebs R; Immendörfer U; Thrall SH; Wöhrl BM; Goody RS
    Biochemistry; 1997 Aug; 36(33):10292-300. PubMed ID: 9254628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
    Miller V; Larder BA
    Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Designing anti-AIDS drugs targeting the major mechanism of HIV-1 RT resistance to nucleoside analog drugs.
    Sarafianos SG; Hughes SH; Arnold E
    Int J Biochem Cell Biol; 2004 Sep; 36(9):1706-15. PubMed ID: 15183339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.